Kono H, Hosomura N, Amemiya H, Shoda K, Furuya S, Akaike H, Kawaguchi Y, Kawaida H, Ichikawa D. Rikkunshito increases appetite by enhancing gastrointestinal and incretin hormone levels in patients who underwent pylorus-preserving pancreaticoduodenectomy: A retrospective study. World J Gastrointest Surg 2023; 15(5): 871-881 [PMID: 37342846 DOI: 10.4240/wjgs.v15.i5.871]
Corresponding Author of This Article
Hiroshi Kono, MD, PhD, Associate Professor, First Department of Surgery, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan. hkouno@yamanashi.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. May 27, 2023; 15(5): 871-881 Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.871
Rikkunshito increases appetite by enhancing gastrointestinal and incretin hormone levels in patients who underwent pylorus-preserving pancreaticoduodenectomy: A retrospective study
Hiroshi Kono, Naohiro Hosomura, Hidetake Amemiya, Katsutoshi Shoda, Shinji Furuya, Hidenori Akaike, Yoshihiko Kawaguchi, Hiromichi Kawaida, Daisuke Ichikawa, First Department of Surgery, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan
Author contributions: Kono H conducted and organized this experiment; Hosomura N Amemiya H and Akaike H made an assessment of samples; Shoda K, Furuya S and Kawaguchi Y analyzed the data; Kawaida H collected the samples; Ichikawa D provided suggestions for this experiment.
Institutional review board statement: This study was approved by University of Yamanashi Hospital Institutional Review Board (Chief of the committee Zentaro Yamagata; and Approval number: 820) and was performed following the ethical standards outlined in the Declaration of Helsinki and its later amendments. Informed consent was obtained from all patients and/or donors of clinical samples, including blood or tissues, where necessary, at the time of admission.
Informed consent statement: All study participants, or their legal guardians, were provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hiroshi Kono, MD, PhD, Associate Professor, First Department of Surgery, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan. hkouno@yamanashi.ac.jp
Received: November 15, 2022 Peer-review started: November 15, 2022 First decision: February 15, 2023 Revised: February 22, 2023 Accepted: April 7, 2023 Article in press: April 7, 2023 Published online: May 27, 2023
The effects of TJ-43 in patients undergoing pancreatic surgery have not been elucidated.
Research objectives
This study investigated the effects of TJ-43 in patients undergoing pylorus-preserving pancreatico-duodenectomy (PpPD).
Research methods
Forty-one patients who underwent PpPD were divided into two groups; patients treated with daily doses of TJ-43 after surgery [TJ-43(+) group] or just on postoperative day (POD) 21 [TJ-43(-) group]. Plasma levels of acylated and desacylated ghrelin, cholecystokinin (CCK), peptide YY (PYY), gastric inhibitory peptide (GIP), and active glucagon-like peptide (GLP)-1 were evaluated. Oral calorie intake was assessed at POD 21 in both groups. The primary endpoint of this study was the total food intake after PpPD.
Research results
The acylated-ghrelin levels were significantly greater in patients treated with TJ-43 than those in patients without TJ-43 treatment at POD 21. Similarly, oral intake significantly increased in the TJ-43(+) group. The levels of CCK and PYY were significantly greater in patients treated with TJ-43 than those in patients without TJ-43 administration. Furthermore, the GIP and active GLP-1 levels increased and the values at POD 21 were significantly greater in patients treated with TJ-43 than those in patients without TJ-43 treatment. Insulin secretion tended to increase in patients treated with TJ-43.
Research conclusions
TJ-43 may improve oral food intake in patients in the early phase after pancreatic surgery.
Research perspectives
Further investigation is needed to clarify the effects of TJ-43 on incretin hormones.
